Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC with Oxaliplatin for Colon Peritoneal Metastases
NCT06681038Phase 2Not yet recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Feb 2025
- Primary completion
- Aug 2029
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of oxaliplatin in colorectal cancer (CRC) (2 arms), sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Progression-Free Survival at 18 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06681038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681038.